Amarpreet Sawhney is the President and CEO of I-Therapeutix, Inc. a company focused on solving unmet needs in ophthalmic surgical wound closure and drug delivery. Prior to this he was Founder and CEO of Confluent Surgical, a biosurgery company, based in Waltham, MA. Confluent was acquired by Tyco Healthcare. Before Confluent, Dr. Sawhney was the technology founder of Focal, Inc. (acquired by Genzyme). Dr. Sawhney’s innovations are the subject of almost 100 issued and pending patents in biomaterials and bio-surgery. His inventions include several “first of a kind” surgical sealants to be approved by the United States FDA and one of them, DuraSeal, was recognized by the FDA as one of the most significant medical device approvals of 2005. In addition to being an entrepreneur Amar, has also created a platform to support other entrepreneurs. He and his partner, Fred Khosravi, have founded Incept LLC, whose vision is to serve as an “enabler” of healthcare entrepreneurs. Incept counts among its companies, Embolic Protection, Inc. (acquired by Boston Scientific), Access Closure, Inc. and Square One Inc. in California, MarketRx Inc. in New Jersey (recently acquired by Cognizant), in addition to I-Therapeutix. Amar currently serves on the board of directors of Square One, Soteira, Access Closure, Augmenix, and I-Therapeutix and is also a Founder of the last three companies. Additionally Amar volunteers his time with other entrepreneurial organizations such as TiE Boston, MassMedic, and the E&Y Entrepreneur of the Year program. Dr. Sawhney and Confluent have been recognized by several awards including the MassMedic best startup company award, Frost and Sullivan Product innovation award, MIT Global Indus Technovators Award, the E&Y regional entrepreneur of the year award, Mass High Tech All Star award, and the University of Texas Outstanding Young Engineering Graduate award. Dr. Sawhney holds an M.S. and a Ph.D. in Chemical Engineering from the University of Texas at Austin and a B. Tech. in Chemical Engineering from the Indian Institute of Technology, New Delhi.
Friday, October 9, 2009
Amar Sawhney: Boston SLP Class
Amarpreet Sawhney is the President and CEO of I-Therapeutix, Inc. a company focused on solving unmet needs in ophthalmic surgical wound closure and drug delivery. Prior to this he was Founder and CEO of Confluent Surgical, a biosurgery company, based in Waltham, MA. Confluent was acquired by Tyco Healthcare. Before Confluent, Dr. Sawhney was the technology founder of Focal, Inc. (acquired by Genzyme). Dr. Sawhney’s innovations are the subject of almost 100 issued and pending patents in biomaterials and bio-surgery. His inventions include several “first of a kind” surgical sealants to be approved by the United States FDA and one of them, DuraSeal, was recognized by the FDA as one of the most significant medical device approvals of 2005. In addition to being an entrepreneur Amar, has also created a platform to support other entrepreneurs. He and his partner, Fred Khosravi, have founded Incept LLC, whose vision is to serve as an “enabler” of healthcare entrepreneurs. Incept counts among its companies, Embolic Protection, Inc. (acquired by Boston Scientific), Access Closure, Inc. and Square One Inc. in California, MarketRx Inc. in New Jersey (recently acquired by Cognizant), in addition to I-Therapeutix. Amar currently serves on the board of directors of Square One, Soteira, Access Closure, Augmenix, and I-Therapeutix and is also a Founder of the last three companies. Additionally Amar volunteers his time with other entrepreneurial organizations such as TiE Boston, MassMedic, and the E&Y Entrepreneur of the Year program. Dr. Sawhney and Confluent have been recognized by several awards including the MassMedic best startup company award, Frost and Sullivan Product innovation award, MIT Global Indus Technovators Award, the E&Y regional entrepreneur of the year award, Mass High Tech All Star award, and the University of Texas Outstanding Young Engineering Graduate award. Dr. Sawhney holds an M.S. and a Ph.D. in Chemical Engineering from the University of Texas at Austin and a B. Tech. in Chemical Engineering from the Indian Institute of Technology, New Delhi.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment